investorscraft@gmail.com

Intrinsic Value of Champions Oncology, Inc. (CSBR)

Previous Close$7.68
Intrinsic Value
Upside potential
Previous Close
$7.68

VALUATION INPUT DATA

This valuation is based on fiscal year data as of 2024 and quarterly data as of .

Data is not available at this time.

Stock Valuation Context

Business Model And Market Position

Champions Oncology, Inc. operates in the biotechnology and precision medicine sector, specializing in oncology-focused solutions. The company generates revenue primarily through its proprietary TumorGraft platform, which provides personalized cancer models for drug development and clinical research. By offering translational oncology services, including preclinical testing and biomarker analysis, Champions Oncology serves pharmaceutical companies, academic institutions, and biotech firms seeking to improve therapeutic outcomes. The company differentiates itself through its patient-derived xenograft (PDX) models, which closely mimic human tumor biology, enhancing the predictive accuracy of drug responses. This positions Champions Oncology as a niche player in the growing precision medicine market, where demand for tailored cancer treatments is rising. Despite competition from larger CROs and diagnostic firms, the company maintains relevance by focusing on high-fidelity models and collaborative research partnerships.

Revenue Profitability And Efficiency

For FY 2024, Champions Oncology reported revenue of $50.2 million, reflecting its core service offerings. However, the company posted a net loss of $7.3 million, with diluted EPS of -$0.54, indicating ongoing profitability challenges. Operating cash flow was negative at $6.1 million, exacerbated by capital expenditures of $0.8 million, underscoring inefficiencies in converting revenue to cash.

Earnings Power And Capital Efficiency

The negative earnings and cash flow highlight strained capital efficiency, with the company struggling to achieve sustainable margins. The reliance on high-cost research services and limited scalability in its PDX model business may constrain near-term earnings improvement without significant operational restructuring or revenue diversification.

Balance Sheet And Financial Health

Champions Oncology holds $2.6 million in cash and equivalents against $7.4 million in total debt, signaling liquidity constraints. The weak cash position relative to debt raises concerns about financial flexibility, particularly given consistent operating losses and minimal free cash flow generation.

Growth Trends And Dividend Policy

Revenue growth trends remain uncertain due to the niche nature of its services and competitive pressures. The company does not pay dividends, reinvesting limited resources into R&D and platform enhancements to sustain its market position.

Valuation And Market Expectations

The market likely prices Champions Oncology based on its specialized technology rather than near-term profitability. Investors may assign value to its PDX platform's long-term potential in drug development, though execution risks and funding needs temper optimism.

Strategic Advantages And Outlook

Champions Oncology's strategic advantage lies in its proprietary TumorGraft technology, which aligns with the shift toward personalized medicine. However, the outlook depends on securing sustainable partnerships, improving cost management, and demonstrating clinical utility to attract broader adoption.

Sources

10-K filing (CIK: 0000771856), company financial disclosures

show cash flow forecast

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year2025202620272028202920302031203220332034203520362037203820392040204120422043204420452046204720482049

INCOME STATEMENT

Revenue growth rate, %NaN
Revenue, $NaN
Variable operating expenses, $mNaN
Fixed operating expenses, $mNaN
Total operating expenses, $mNaN
Operating income, $mNaN
EBITDA, $mNaN
Interest expense (income), $mNaN
Earnings before tax, $mNaN
Tax expense, $mNaN
Net income, $mNaN

BALANCE SHEET

Cash and short-term investments, $mNaN
Total assets, $mNaN
Adjusted assets (=assets-cash), $mNaN
Average production assets, $mNaN
Working capital, $mNaN
Total debt, $mNaN
Total liabilities, $mNaN
Total equity, $mNaN
Debt-to-equity ratioNaN
Adjusted equity ratioNaN

CASH FLOW

Net income, $mNaN
Depreciation, amort., depletion, $mNaN
Funds from operations, $mNaN
Change in working capital, $mNaN
Cash from operations, $mNaN
Maintenance CAPEX, $mNaN
New CAPEX, $mNaN
Total CAPEX, $mNaN
Free cash flow, $mNaN
Issuance/(repurchase) of shares, $mNaN
Retained Cash Flow, $mNaN
Pot'l extraordinary dividend, $mNaN
Cash available for distribution, $mNaN
Discount rate, %NaN
PV of cash for distribution, $mNaN
Current shareholders' claim on cash, %NaN
HomeMenuAccount